INTRODUCTION {#s1}
============

Gastric cancer (GC) is one of the most common cancers and the leading causes of cancer death in the world \[[@R1]\], however, there is a gradually decrease in incidence and mortality rates in most developed countries \[[@R2]\]. GC is a multifactorial disease caused by dietary, genetic and environmental factors \[[@R3], [@R4]\]. Although the pathogenetic mechanism of GC is very complicated and is still not fully understood, more and more evidence has been shown that there is a correlation between genetic polymorphisms and GC risk \[[@R5]--[@R7]\].

To date, many genetic polymorphisms in the carcinogen detoxification, antioxidant protection, DNA repair and cell proliferation processes have been reported to play a crucial role in the development of GC \[[@R8]\]. The *human 8-oxoguanine glycosylase 1* (*hOGG1*) gene, specifically involved in the repair of DNA oxidative damage in the base excision response pathway, has been shown to be associated with a variety of cancers \[[@R9]--[@R13]\]. As an important component of DNA repair pathway, *hOGG1* encodes a DNA glycosylase enzyme that actively removes 8-hydroy-2-deoxyguanine, which is highly mutagenic and a major form of oxidative DNA damage \[[@R14], [@R15]\]. The dysfunction of hOGG1 might result in the DNA repair deficiency and then induce gene mutation and cell canceration. Functional studies showed that the hOGG1 variant had normal enzymatic activity, but maintained greater sensitivity to oxidation than wildtype hOGG1 protein \[[@R16]\].

The *hOGG1* gene has been regarded as a candidate for involvement in the underlying cause of GC and the *hOGG1* polymorphism rs1052133 has been widely evaluated in association with GC across different ethnicities \[[@R11], [@R17]--[@R31]\]. *hOGG1* polymorphism rs1052133 has been reported to be associated with an altered risk for GC in Chinese, Japanese and Caucasian populations \[[@R11], [@R18], [@R19], [@R32]\]. However, other reported studies on the association between *hOGG1* rs1052133 and GC risk are inconclusive and conflicting \[[@R20]--[@R31]\]. Such inconsistence and heterogeneity could be caused by different sample sizes and diversities in multiple ethnic cohorts. Meta-analysis, which combined all studies with the same criteria, could be helpful to comprehensively explain the association of *hOGG1* rs1052133 with GC and provide some new clues for the research on GC. Therefore, in this study we conduct a systematic review and meta-analysis of all association studies on *hOGG1* rs1052133 with GC, to summarize and evaluate the association between *hOGG1* rs1052133 and GC.

RESULTS {#s2}
=======

Literature search and characteristics {#s2_1}
-------------------------------------

A flow diagram (Figure [1](#F1){ref-type="fig"}) shows the selection process of studies included in our analysis. The initial search strategy yielded 31 articles. Among them, two review articles were excluded because of the publication type and six articles were excluded because of unrelated topics. The full text of the remaining 23 studies was retrieved and reviewed. Eight articles were excluded after full-text review, five studies were not case-control studies and three articles were experimental studies. Finally, 15 articles were identified that met the inclusion criteria and included for the meta-analysis. The analyzed SNP was successfully genotyped and was within HWE (except the genotype in control subjects from the Takezaki\'s study) across all the included studies. All of the articles were case-control studies and all the cases were histopathologically confirmed as GC. The characteristics of these included articles are listed in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. The NOS results showed that the score ranged from 7 to 8 with an average of 7.50, which indicated that the methodological quality of these selected articles was generally reliable.

![Flow diagram of literature search and study selection for meta-analysis](oncotarget-08-34321-g001){#F1}

###### Characteristics of the fifteen studies included in this meta-analysis

  Study                   Country   Study population         Ethnicity   Study design   Genotyping method   Mean Age    NOS                         
  ----------------------- --------- ------------------------ ----------- -------------- ------------------- ----------- ------------- ------------- ---
  Lu, et al. 2016         China     Chinese                  Asian       CB             HB                  SNaPshot    63.1 ± 10.7   63.3 ± 11.0   8
  Hu, et al. 2015         China     Chinese                  Asian       HB             HB                  PCR-LDR     −             −             8
  Engin, et al. 2011      Turkey    Turkish                  Others      HB             HB                  PCR-RFLP    60.4 ± 1.3    55.5 ±1.3     7
  Liu, et al. 2011        China     Chinese                  Asian       HB             CB                  PCR-HMR     60.2 ± 10.4   59.3 ± 11.8   8
  Canbay, et al. 2010     Turkey    Turkish                  Others      CB             PB                  PCR-RFLP    60.1 ± 20.9   52.8 ± 27.2   8
  Sun, et al. 2010        China     Chinese                  Asian       HB             PB                  PCR-RFLP    59.6 ± 11.2   43.6 ± 10.3   7
  Malik, et al. 2010      India     Indian                   Asian       CB             PB                  PCR-SSCP    55.9 ± 9.7    58.0 ±12.7    7
  Palli, et al. 2010      Italy     Italian                  Caucasian   CB             PB                  Taqman      68.8 ± 9.9    55.5 ± 7.0    7
  Farinati, et al. 2008   Italy     Italian                  Caucasian   CB             PB                  PCR-RFLP    68            46            8
  Capella, et al. 2008    Spain     Spanish                  Caucasian   CB             PB                  Probe       50.5 ± 20.5   50.5 ± 20.5   8
  Poplawskiet al. 2006    Poland    Polish                   Caucasian   HB             PB                  PCR-SSCP    62.4 ± 27.4   62.4 ± 27.4   8
  Tsukino, et al. 2004    Japan     Japanese                 Asian       HB             HB                  PCR-SSCP    57.5 ± 9.5    57.1 ± 9.5    7
  Takezaki, et al. 2002   China     Chinese                  Asian       CB             PB                  PCR- SSCP   65 ± 15       65 ± 14       7
  Hanaoka, et al. 2001    Japan     Japanese Brazilian       Others      HB             HB                  PCR-SSCP    65 ± 13       65 ± 12       7
  Hanaoka, et al. 2001    Japan     non-Japanese Brazilian   Others      HB             HB                  PCR-SSCP    59 ± 8        58 ± 8        8
  Shinmura, et al. 1998   Japan     Japanese                 Asian       HB             PB                  PCR-SSCP    −             −             7

PB, population based; CB, clinic or institute based; HB, hospital based; NOS, Newcastle-Ottawa Scale; -Data unavailable.

###### Genotype frequencies of hOGG1 rs1052133 among gastric cancer cases and controls in the included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                    Sample size   Genotypes (Case)   Genotypes (Control)   Allele Frequency (G)   OR, 95%CI\        *P*                                                   
                                                                                                         (Allellc Model)                                                         
  ------------------------ ------------- ------------------ --------------------- ---------------------- ----------------- ----- ----- ----- ------- ------- ------------------- -------
  Lu, et al. 2016          1279          1434               477                   591                    211               525   702   207   0.396   0.389   0.97 (0.87--1.08)   0.604

  Hu, et al. 2015          436           372                154                   210                    72                128   176   68    0.406   0.419   1.06 (0.87--1.29)   0.586

  Engin, et al. 2011       106           116                53                    42                     11                51    47    18    0.302   0.358   1.29 (0.87--1.92)   0.211

  Liu, et al. 2011         618           913                114                   302                    202               144   447   322   0.571   0.594   1.10 (0.95--1.27)   0.199

  Canbay, et al. 2010      40            247                24                    13                     3                 171   69    7     0.238   0.168   0.65 (0.37--1.14)   0.131

  Sun, et al. 2010         73            255                21                    19                     33                72    119   64    0.582   0.484   0.67 (0.46--0.98)   0.037

  Malik, et al. 2010       108           195                50                    51                     7                 94    89    12    0.301   0.290   0.95 (0.66--1.36)   0.772

  Palli, et al. 2010       304           545                192                   101                    11                325   191   29    0.202   0.228   1.17 (0.92--1.49)   0.212

  Farinati, et al. 2008    50            43                 33                    15                     2                 36    7     0     0.190   0.081   0.38 (0.15--0.95)   0.033

  Capella, et al. 2008     438           1026               279                   137                    22                621   352   53    0.207   0.223   1.10 (0.91--1.34)   0.320

  Poplawski, et al. 2006   28            33                 22                    6                      0                 18    15    0     0.107   0.227   2.45 (0.88--6.82)   0.079

  Tsukino, 2004            142           271                32                    75                     35                74    141   56    0.511   0.467   0.84 (0.63--1.12)   0.232

  Takezaki, 2002           101           198                20                    61                     20                30    120   48    0.500   0.545   1.20 (0.85--1.68)   0.292

  Hanaoka, 2001            58            127                20                    29                     9                 44    56    27    0.405   0.433   1.12 (0.72--1.75)   0.614

  Hanaoka, 2001            208           205                133                   67                     8                 123   74    8     0.200   0.220   1.13 (0.81--1.58)   0.480

  Shinmura, 1998           35            42                 9                     16                     10                15    20    7     0.514   0.405   0.64 (0.34--1.22)   0.174
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MAF, minor allele frequency; OR, odds ratio; CI, confidence intervals; P, *p* value for *Z* test.

Meta-analysis results {#s2_2}
---------------------

Fifteen studies provided results of the association of *hOGG1* rs1052133 with GC and a total of 10046 subjects (4024GC patients and 6022 controls) were tested for *hOGG1* rs1052133 in this meta analysis. Stratified analyses were conducted based on three groups, including Asian \[[@R11], [@R18], [@R24], [@R26], [@R27], [@R29]--[@R31]\], Caucasian \[[@R19], [@R21], [@R22], [@R25]\] and other ethnicities \[[@R20], [@R23], [@R28]\], and the heterogeneity of *hOGG1* rs1052133 in Asian, Caucasian, other and pooled populations were evaluated firstly. The results showed low heterogeneity for the included populations under all the genetic models by fixed-effect analysis, except for the Caucasian population under allelic genetic model (*P* = 0.052, *I^2^* = 61.2%), the Asian population under recessive model (*P* = 0.021, *I^2^* = 57.6%) and Caucasian population under dominant model (*P* = 0.054, *I^2^* = 60.7%), the random-effect analysis was thus adopted for them under each genetic model (Table [3](#T3){ref-type="table"}).

###### Pooled measure for the association of hOGG1 rs1052133 and gastric cancer different allelic models

  Genetic model                      Ethnicity              Pooled OR( 95% CI)     Heterogeneity   Test for overall effect   Begg test           
  ---------------------------------- ---------------------- ---------------------- --------------- ------------------------- ----------- ------- -------
  Allelic model ( C vs. G)           Asian                  0.979 (0.879--1.091)   0.121           38.8                      0.38        0.705   0.344
  CaucasianΔ                         1.085 (0.789--1.492)   0.052                  61.2            0.50                      0.616               
  others                             1.072 (0.841--1.366)   0.265                  24.4            0.56                      0.574               
  Overall                            1.016 (0.924--1.117)   0.046                  40.6            0.32                      0.746               
  Addictive model (CC vs. GG)        Asian                  0.973 (0.839--1.130)   0.127           38.0                      0.35        0.723   0.235
  Caucasian                          1.171 (0.778--1.764)   0.351                  4.5             0.76                      0.450               
  others                             1.210 (0.736--1.989)   0.261                  25.0            0.75                      0.452               
  Overall                            1.010 (0.883--1.155)   0.186                  24.2            0.14                      0.888               
  Recessive model (CC + GC vs. GG)   AsianΔ                 0.939 (0.830--1.064)   0.021           57.6                      1.01        0.313   0.322
  Caucasian                          1.128 (0.752--1.692)   0.405                  0.0             0.61                      0.543               
  others                             1.223 (0.765--1.956)   0.300                  18.1            0.53                      0.594               
  Overall                            0.969 (0.864--1.087)   0.052                  40.5            0.48                      0.628               
  Dominant model (CC vs. GG +GC)     Asian                  1.039 (0.930--1.160)   0.692           0.0                       0.68        0.498   0.260
  CaucasianΔ                         1.136 (0.954--1.353)   0.054                  60.7            1.43                      0.152               
  others                             1.079 (0.828--1.404)   0.470                  0.0             0.56                      0.575               
  Overall                            1.067 (0.977--1.165)   0.408                  4.0             1.45                      0.147               

\* OR, odds ratio; CI, confidence intervals; P, *p* value for *Z* test; *I*^2^ (%), the value to identify heterogeneity.

Δ Pooling model is random effect (Inverse Variance heterogeneity).

▲ Continuity corrected.

Our meta-analysis showed that there was no significant association of *hOGG1* rs1052133 with GC in the overall pooled populations under all the genetic models (Allelic model: C vs. G, OR = 1.016, 95% CI 0.924 to 1.117, *p* = 0.746; *I^2^* = 40.6;Addictive model: CC vs. GG, OR = 1.010, 95% CI 0.883 to 1.155, *p* = 0.888; *I^2^* = 24.2; Recessive model: CC +GC vs. GG, OR = 0.969, 95% CI 0.864 to 1.087, *p* = 0.628; *I^2^* = 40.5; Dominant model: CC vs. GG+GC, OR = 1.067, 95% CI 0.977 to 1.165, *p* = 0.147; *I^2^* = 4; Table [3](#T3){ref-type="table"}). Figure [2](#F2){ref-type="fig"} shows the forest plot of estimates of odds ratios of the association of *hOGG1* rs1052133 with GC. When stratified analyses were conducted to explore further association of *hOGG1* rs1052133 with GC in different ethnicities under each genetic model, no significant association was detected between *hOGG1* rs1052133 and GC, either (Table [3](#T3){ref-type="table"} and Figure [2B--2D](#F2){ref-type="fig"}).

![Forest plots for meta-analysis of *hOGG1* rs1052133 and the risk for GC\
(**A**) allelic model (C vs. G); (**B**) addictive genetic model (CC vs. GG); (**C**) recessive genetic model (CC + GC vs. GG); (**D**) dominant genetic model (CC vs. GG+GC).](oncotarget-08-34321-g002){#F2}

Publication bias and sensitivity analysis {#s2_3}
-----------------------------------------

Publication biases were assessed by the Egger\'s test quantitatively and the result for *hOGG1* rs1052133 based on the 15 included studies did not observe any obvious evidence of publication bias in the overall analyses under all genetic models (Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}). The effect of each study on the pooled OR was also assessed by sequential omission of individual studies. We did not find that the exclusion of any single study alter the significance of the final pooled OR.

![Funnel plot analysis for publication bias between *hOGG1* rs1052133 and GC risk\
P for publication bias of this funnel plot for dominant model (CCvs.GG+GC) with all 15 studies is 0.260.](oncotarget-08-34321-g003){#F3}

DISCUSSION {#s3}
==========

As a powerful statistical method, meta-analysis could provide a quantitative approach for pooling the variant results on the same topic to estimate and explain their diversity. This led us to conduct this meta-analysis of 15 published case-control studies, which may help us in distinguishing the truth from the false, and to explore a more robust estimate of the effect of *hOGG1* rs1052133 on GC. The *hOGG1* rs1052133 has been thought to constitute a candidate genetic risk factor for GC \[[@R11], [@R18], [@R19], [@R32]\]; however, several other studies have investigated the genetic effect of *hOGG1* rs1052133 on GC susceptibility with conflicting results \[[@R20]--[@R31]\]. In this study, our meta-analysis showed there was no association between *hOGG1* rs1052133 and GC in all genetic models, suggesting that *hOGG1* rs1052133 may not affect individual susceptibility to GC.

GC is considered to be a common, complex and multifactorial disease, and is estimated to have a significant heritable component. GC ranks as the third leading cause of cancer mortality worldwide and confers a 5-year survival of 20% \[[@R33]\]. Identifying causative genes has helped to understand the disease process and may aid in prevention. About 1%--3% of GC could be attributed to inherited cancer predisposition syndromes. More advances have been made in human GC genetics, but there is still to be known \[[@R8]\]. To date, Germline E-cadherin/CDH1 mutations have been identified in families with an autosomal dominant inherited predisposition to diffuse GC \[[@R34]\]. *hOGG1* has been reported to be related to GC risk in several studies \[[@R11], [@R18], [@R19], [@R32]\]. It is an important glycosylase enzyme that plays a critical role in the repair of DNA oxidative damage \[[@R14], [@R15]\]. The dysfunction of hOGG1 might lead to deficiency of DNA repair and result in cell canceration. hOGG1 variant has been shown to exhibit lower DNA repair activity and greater sensitivity to oxidation than wildtype hOGG1 protein \[[@R16]\].

The association between *hOGG1* rs1052133 and GC in previous studies were inconsistent. *hOGG1* rs1052133 was reported to be significantly associated with GC in Japanese and Chinese patients with GC \[[@R11], [@R18], [@R19], [@R32]\]. However, no evidence of association between *hOGG1* rs1052133 and GC was detected in Turkish, Spanish, Italian, Polish and Indian studies \[[@R21]--[@R25], [@R28]\], meanwhile, the association of *hOGG1* rs1052133 with GC was not replicated in other Japanese and Chinese populations \[[@R20], [@R26], [@R27]\]. Recently, the association between *hOGG1* rs1052133 with GC risks was also accessed in Lu *et al*' study with 1,275 GC patients and 1,436 controls \[[@R29]\] and in Hu *et al*\'s study with 2745 GC patients and 4588 controls \[[@R30]\], respectively. Both the two studies demonstrated that the significant association was not present between *hOGG1* rs1052133 and GC. In order to provide powerful statistical analysis, we conduct this study with more samples (a total of 4024GC patients and 6022 controls) to evaluate the association between *hOGG1* rs1052133 and GC. Our results did not show any significant association of *hOGG1* rs1052133 with GC, even across different ethnic populations. Therefore, our analyses failed to conclude whether *hOGG1* rs1052133 is really a GC-associated SNP and more replication data is needed to validate this association. Of course, other factors, such as environment and different lifestyle, might play roles in these differences as well. Further analysis should be performed in more large-scale cohorts or case-control studies to explore the association of *hOGG1* rs1052133 with GC. Future studies on gene-environment interaction should also be considered.

This systematic review and meta-analysis has sufficient power to evaluate and review all the published genetics studies in *hOGG1* rs1052133, however, some potential limitations of our study on the understanding of *hOGG1* in GC genetics should be considered. (1) This meta-analysis was mainly based on the studies with 2950 GC patients and 3817 controls in Japanese and Chinese populations \[[@R11], [@R18], [@R20], [@R26], [@R27], [@R29]--[@R31]\]. Besides, only 1074 GC patients and 2205 controls in Turkish, Indian, Italian, Spanish and Polish populations were included in the present study. It may restrict our conclusions which indicate the need for larger sample sizes in other ethnic populations. (2) There was a high heterogeneity detected in the Caucasian population under allelic genetic model, in the Asian population under addictive model and in the Caucasian population under dominant model. It is possible that different populations with different clinical patient characteristics were included. (3) GC is a multifactorial disease that results from complex interactions between various genetic factors and other factors. Therefore, our results may be influenced by confronting factors, such as age, gender, environment, and lifestyle. If the investigation of gene-environment interactions in different ethnic subgroups could be carried out, we might get more conclusive claims about the association of *hOGG1* rs1052133 with GC.

In conclusion, this meta-analysis showed that *hOGG1* rs1052133 is not associated with GC under all the genetic models, suggesting that it may not affect individual susceptibility to GC. Further investigations with larger sample sizes and more ethnic groups are required to validate the association and confirm the roles of *hOGG1* in GC.

MATERIALS AND METHODS {#s4}
=====================

Searching strategy {#s4_1}
------------------

A systematic literature search using the databases PubMed, Embase, Web of Science, and the Chinese Biomedical Database was conducted, to identify all published studies on the association of *hOGG1* polymorphisms with GC from their starting date to December 15, 2016. Following keywords were used: ''cancer,'' ''gastric cancer,'' ''human 8-oxoguanine glycosylase,'' ''hOGG1,'' ''rs1052133,'' ''polymorphism(s),'' ''variant(s),'' and ''mutation(s).'' The internet was searched using the Google search engine. Reference lists of the retrieved articles and reviews were manually checked for additional articles, to identify studies not yet included in the electronic searches.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The eligible articles were considered if they (1) evaluated associations between *hOGG1* rs1052133 and GC; (2) used a case--control design to compare GC cases and normal controls in defined populations; (3) gave an OR with 95% CI or other available data from which they could be estimated; and (4) were original research articles, not reviews or comments. Excluded were abstracts from conferences, full texts without raw data available for retrieval, republished data, duplicate studies and reviews.

Data extraction {#s4_3}
---------------

Two observers (DDZ and XNG) independently abstracted data from all eligible publications onto paper data collection forms. Two reviewers (JLH and GQZ) were blinded to the details (title, author, and academic address) of these studies during assessment. Disagreements were resolved by discussion until a consensus was achieved. Otherwise, a third investigator was consulted to resolve the dispute. The following items were collected from each study: first author\'s surname, year of publication, statistical data, ethnicity of subjects, whether Hardy-Weinberg equilibrium (HWE) was examined in controls, genotyping method, total numbers of cases and controls, as well as total numbers of cases and controls for each *hOGG1*genotypes, respectively.

Quality assessment {#s4_4}
------------------

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included studies by two investigators independently. Through the rating system, the NOS was conducted to judge the study quality based on three aspects, which were selection, comparability, and exposure situation in case-control studies. Rating scores range from 0 (worst) to 9 (best). Studies with a score of 7 or greater were thought to have an adequate or good quality.

Statistical analysis {#s4_5}
--------------------

A pooled OR with its corresponding 95% CI was used as a measure of the association of *hOGG1* rs1052133 with GC. For genotypic comparison, allelic, addictive, dominant and recessive models were applied in the investigation of the disease association. We conducted stratified analyses by ethnicity, including Asian populations (Japanese, Chinese and Indian), Caucasian populations (Polish, Italian and Spanish), other populations (Turkish, Japanese Brazilian and non-Japanese Brazilian) and pooled populations. Sensitivity analysis was carried out by excluding one study at a time to explore whether the results were influenced by a specific study. Heterogeneity (between-study inconsistency) was investigated and measured using *I^2^* statistic. A *p* value of *I^2^* \< 50% indicated an absence of heterogeneity among studies, the fixed-effect model (Mantel-Haenszel method) was thus used to calculate the pooled ORs. In contrast, if the *p* value for heterogeneity was *I^2^* ≥ 50%, indicating a high degree of heterogeneity between studies, then the random-effect model (DerSimonian-Laird method) was used to evaluate the summary ORs. Begg liner regression test was used to assess the potential publication bias, where a value of *p* \< 0.05 was considered statistically significant. The Hardy-Weinberg equilibrium (HWE) for each SNP was tested by the χ^2^ test. All statistical analyses were performed by the Review Manager software (RevMan, version 5.2; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen;2012), and the STATA software (version 12.0, STATA Corp., College Station, TX, USA), as well as the Hardy Weinberg package (version 1.3) in R language (version 2.15.0,<http://cran.r-project.org/>). Two-sided *P* values \< 0.05 were considered statistically significant.
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